Merck Gets Second Chance On Dual PPAR: Will Co-Develop Bristol's Muraglitazar
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol cites shift in focus to specialty care as one reason to out-license the product. Merck will pay $100 mil. upfront and $275 mil. in milestone payments for rights to the dual PPAR agonist and a back-up compound in Phase II.
You may also be interested in...
Bristol Continues To Refocus Marketing By Outsourcing Cefzil And Tequin
Ventiv will commit 375 reps to focus on the primary care market while Bristol will continue to sell the antibiotics to specialists in hospitals. The two companies had terminated a previous co-promotion agreement for Cefzil; the new contract is fee-for-service and does not include risk sharing.
Bristol Continues To Refocus Marketing By Outsourcing Cefzil And Tequin
Ventiv will commit 375 reps to focus on the primary care market while Bristol will continue to sell the antibiotics to specialists in hospitals. The two companies had terminated a previous co-promotion agreement for Cefzil; the new contract is fee-for-service and does not include risk sharing.
Bristol Expects FDA Advisory Committee Review Of Muraglitazar
Bristol-Myers Squibb expects FDA will hold an advisory committee meeting to discuss the application for its dual PPAR agonist muraglitazar